Cantor Fitzgerald Reiterates “Overweight” Rating for Aardvark Therapeutics (NASDAQ:AARD)
Aardvark Therapeutics (NASDAQ:AARD – Get Free Report)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $50.00 price objective on the stock. Cantor Fitzgerald’s price target suggests a potential upside of 434.76% from the stock’s current price. Several other […]
Aardvark Therapeutics (NASDAQ:AARD – Get Free Report)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $50.00 price objective on the stock. Cantor Fitzgerald’s price target suggests a potential upside of 434.76% from the stock’s current price. Several other […]
